Moderna (NASDAQ:MRNA) executives highlighted progress on cost reductions, a ramp in international partnerships, and multiple late-stage pipeline milestones during the company’s fourth-quarter 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results